Genitourinary Drugs Market By Indication (Prostate, Ovarian, Bladder, Cervical Cancer, Erectile Dysfunction, UTI, Urinary Incontinence & STD) By Product (Urologicals, Hormonal Therapy Drugs, Gynecological, Anti-infectives) And Segment Forecasts, 2018 - 2024

Table of Content

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
Chapter 2. Executive Summary
Chapter 3. Market Snapshot
Chapter 4. Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Driver Analysis
4.2.1. Increasing number of pipeline drugs
4.2.2. Growing prevalence of genitourinary disorders
4.3. Market Restraint Analysis
4.3.1. Increasing advent of counterfeit drugs
4.3.2. Growing generics drug competition
4.3.3. High number of patent expirations in the coming years
4.4. Penetration & Growth Prospect Mapping
4.5. Genitourinary Drugs - SWOT Analysis, By Factor (political & legal, economic and technological)
4.6. Industry Analysis - Porter's
Chapter 5. Market Categorization 1: Indication Estimates & Trend Analysis
5.1. Genitourinary Drugs Market: Indication Movement Analysis
5.2. Prostate Cancer
5.2.1. Prostate cancer market estimates and forecasts, 2013 - 2024 (USD Million)
5.3. Ovarian Cancer
5.3.1. Ovarian cancer market estimates and forecasts, 2013 - 2024 (USD Million)
5.4. Bladder Cancer
5.4.1. Bladder cancer market estimates and forecasts, 2013 - 2024 (USD Million)
5.5. Cervical Cancer
5.5.1. Cervical cancer market estimates and forecasts, 2013 - 2024 (USD Million)
5.6. Renal Cancer
5.6.1. Renal cancer market estimates and forecasts, 2013 - 2024 (USD Million)
5.7. Erectile Dysfunction
5.7.1. Erectile dysfunction market estimates and forecasts, 2013 - 2024 (USD Million)
5.8. Urinary Tract Infections
5.8.1. Urinary tract infections market estimates and forecasts, 2013 - 2024 (USD Million)
5.9. Urinary Incontinence & Overactive Bladder
5.9.1. Urinary incontinence & overactive bladder market estimates and forecasts, 2013 - 2024 (USD Million)
5.10. Sexually Transmitted Diseases
5.10.1. Sexually transmitted diseases market estimates and forecasts, 2013 - 2024 (USD Million)
5.11. Interstitial Cystitis
5.11.1. Interstitial cystitis market estimates and forecasts, 2013 - 2024 (USD Million)
5.12. Hematuria
5.12.1. Hematuria market estimates and forecasts, 2013 - 2024 (USD Million)
5.13. Benign Prostatic Hyperplasia
5.13.1. Benign Prostatic Hyperplasia market estimates and forecasts, 2013 - 2024 (USD Million)
Chapter 6. Market Categorization 2: Product Estimates & Trend Analysis
6.1. Genitourinary Drugs Market: Product Movement Analysis
6.2. Urologicals
6.2.1. Urologicals market estimates and forecasts, 2013 - 2024 (USD Million)
6.3. Hormonal Therapy Drugs
6.3.1. Hormonal therapy drugs market estimates and forecasts, 2013 - 2024 (USD Million)
6.4. Gynecological
6.4.1. Gynecological market estimates and forecasts, 2013 - 2024 (USD Million)
6.5. Anti-infectives
6.5.1. Anti-infectives market estimates and forecasts, 2013 - 2024 (USD Million)
6.6. Others
6.6.1. Others market estimates and forecasts, 2013 - 2024 (USD Million)
Chapter 7. Market Categorization 3: Regional Estimates & Trend Analysis, By Indication & Product
7.1. Genitourinary Drugs Market Share By Region, 2015 & 2024
7.2. North America
7.2.1. North America market estimates and forecasts, by indication, 2013 - 2024 (USD Million)
7.2.1.1. U.S. market estimates and forecasts
7.2.1.2. Canada market estimates and forecasts
7.2.2. North America market estimates and forecasts, by product, 2013 - 2024 (USD Million)
7.2.2.1. U.S. market estimates and forecasts
7.2.2.2. Canada market estimates and forecasts
7.3. Europe
7.3.1. Europe market estimates and forecasts, by indication, 2013 - 2024 (USD Million)
7.3.1.1. UK market estimates and forecasts
7.3.1.2. Germany market estimates and forecasts
7.3.2. Europe market estimates and forecasts, by product, 2013 - 2024 (USD Million)
7.3.2.1. UK market estimates and forecasts
7.3.2.2. Germany market estimates and forecasts
7.4. Asia Pacific
7.4.1. Asia Pacific market estimates and forecasts, by indication, 2013 - 2024 (USD Million)
7.4.1.1. Japan market estimates and forecasts
7.4.1.2. China market estimates and forecasts
7.4.1.3. India market estimates and forecasts
7.4.2. Asia Pacific market estimates and forecasts, by product, 2013 - 2024 (USD Million)
7.4.2.1. Japan market estimates and forecasts
7.4.2.2. China market estimates and forecasts
7.4.2.3. India market estimates and forecasts
7.5. Latin America
7.5.1. Latin America market estimates and forecasts, by indication, 2013 - 2024 (USD Million)
7.5.1.1. Brazil market estimates and forecasts
7.5.1.2. Mexico market estimates and forecasts
7.5.2. Latin America market estimates and forecasts, by product, 2013 - 2024 (USD Million)
7.5.2.1. Brazil market estimates and forecasts
7.5.2.2. Mexico market estimates and forecasts
7.6. MEA
7.6.1. MEA market estimates and forecasts, by indication, 2013 - 2024 (USD Million)
7.6.1.1. South Africa market estimates and forecasts
7.6.2. MEA market estimates and forecasts, by product, 2013 - 2024 (USD Million)
7.6.2.1. South Africa market estimates and forecasts
Chapter 8. Competitive Landscape
8.1. Market Participation Categorization
8.2. Company Profiles
8.2.1. Abbott
8.2.1.1. Company overview
8.2.1.2. Financial performance
8.2.1.3. Product benchmarking
8.2.1.4. Strategic initiatives
8.2.2. Bristol-Myers Squibb Co.
8.2.2.1. Company overview
8.2.2.2. Financial performance
8.2.2.3. Product benchmarking
8.2.2.4. Strategic initiatives
8.2.3. Novartis AG
8.2.3.1. Company overview
8.2.3.2. Financial performance
8.2.3.3. Product benchmarking
8.2.3.4. Strategic initiatives
8.2.4. Genentech, Inc.
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Product benchmarking
8.2.4.4. Strategic initiatives
8.2.5. F. Hoffmann-La Roche Ltd
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Product benchmarking
8.2.5.4. Strategic initiatives
8.2.6. Ionis Pharmaceuticals, Inc.
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Product benchmarking
8.2.6.4. Strategic initiatives
8.2.7. Eli Lilly and Company
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Product benchmarking
8.2.7.4. Strategic initiatives
8.2.8. Merck & Co., Inc.
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Product benchmarking
8.2.8.4. Strategic initiatives
8.2.9. Pfizer, Inc.
8.2.9.1. Company overview
8.2.9.2. Financial performance
8.2.9.3. Product benchmarking
8.2.9.4. Strategic initiatives
8.2.10. AstraZeneca
8.2.10.1. Company overview
8.2.10.2. Financial performance
8.2.10.3. Product benchmarking
8.2.10.4. Strategic initiatives
8.2.11. GlaxoSmithKline
8.2.11.1. Company overview
8.2.11.2. Financial performance
8.2.11.3. Product benchmarking
8.2.11.4. Strategic initiatives
8.2.12. Teva Pharmaceutical Industries Ltd.
8.2.12.1. Company overview
8.2.12.2. Financial performance
8.2.12.3. Product benchmarking
8.2.12.4. Strategic initiatives
8.2.13. Bayer AG
8.2.13.1. Company overview
8.2.13.2. Financial performance
8.2.13.3. Product benchmarking
8.2.13.4. Strategic initiatives
8.2.14. Allergan
8.2.14.1. Company overview
8.2.14.2. Financial performance
8.2.14.3. Product benchmarking
8.2.14.4. Strategic initiatives
8.2.15. Antares Pharma
8.2.15.1. Company overview
8.2.15.2. Financial performance
8.2.15.3. Product benchmarking
8.2.15.4. Strategic initiatives

List of Tables

TABLE 1 Country share estimation
TABLE 2 North America genitourinary drugs market, by indication, 2013 - 2024 (USD Million)
TABLE 3 North America genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 4 U.S. genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 5 U.S. genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 6 Canada genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 7 Canada genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 8 Europe genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 9 Europe genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 10 Germany genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 11 Germany genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 12 UK genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 13 UK genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 14 Asia Pacific genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 15 Asia Pacific genitourinary drugs market, by product, 2013 - 2024 (USD Million)
表16日本泌尿生殖器的毒品市场,incidence, 2013 - 2024 (USD Million)
TABLE 17 Japan genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 18 China genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 19 China genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 20 India genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 21 India genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 22 Latin America genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 23 Latin America genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 24 Brazil genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 25 Brazil genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 26 Mexico genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 27 Mexico genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 28 MEA genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 29 MEA genitourinary drugs market, by product, 2013 - 2024 (USD Million)
TABLE 30 South Africa genitourinary drugs market, by incidence, 2013 - 2024 (USD Million)
TABLE 31 South Africa genitourinary drugs market, by product, 2013 - 2024 (USD Million)

List of Figures

FIG. 1 Market summary (USD Million)
FIG. 2 Market trends & outlook
FIG. 3 Market segmentation & scope
FIG. 4 Market driver relevance analysis (Current & future impact)
FIG. 5 Market restraint relevance analysis (Current & future impact)
FIG. 6 Penetration & growth prospect mapping
图7 SWOT分析,通过因子(政治和法律, economic and technological)
FIG. 8 Porter’s Five Forces Analysis
FIG. 9 Genitourinary drugs market incidence outlook key takeaways
FIG. 10 Genitourinary drugs market: Incidence movement analysis
FIG. 11 Global prostate cancer market, 2013 - 2024 (USD Million)
FIG. 12 Global ovarian cancer market, 2013 - 2024 (USD Million)
FIG. 13 Global bladder cancer market, 2013 - 2024 (USD Million)
FIG. 14 Global cervical cancer market, 2013 - 2024 (USD Million)
FIG. 15 Global renal cancer market, 2013 - 2024 (USD Million)
FIG. 16 Global erectile dysfunction market, 2013 - 2024 (USD Million)
FIG. 17 Global urinary tract infections market, 2013 - 2024 (USD Million)
FIG. 18 Global urinary incontinence & overactive bladder market, 2013 - 2024 (USD Million)
FIG. 19 Global sexually transmitted diseases market, 2013 - 2024 (USD Million)
FIG. 20 Global interstitial cystitis market, 2013 - 2024 (USD Million)
FIG. 21 Global hematuria market, 2013 - 2024 (USD Million)
FIG. 22 Global benign prostatic hyperplasia market, 2013 - 2024 (USD Million)
FIG. 23 Genitourinary drugs market product outlook: Key takeaways
FIG. 24 Genitourinary drugs market: Product movement analysis
FIG. 25 Global urologicals market, 2013 - 2024 (USD Million)
FIG. 26 Global hormonal therapy drugs market, 2013 - 2024 (USD Million)
FIG. 27 Global gynecological market, 2013 - 2024 (USD Million)
FIG. 28 Global anti-infectives market, 2013 - 2024 (USD Million)
FIG. 29 Global others market, 2013 - 2024 (USD Million)
FIG. 30 Regional market place: Key takeaways
FIG. 31 Regional outlook, 2015 & 2024
FIG. 32 North America genitourinary drugs market, 2013 - 2024 (USD Million)
FIG. 33 U.S. genitourinary drugs market, 2013 - 2024 (USD Million)
FIG. 34 Canada genitourinary drugs market, 2013 - 2024 (USD Million)
FIG. 35 Europe genitourinary drugs market, 2013 - 2024 (USD Million)
FIG. 36 Germany genitourinary drugs market, 2013 - 2024 (USD Million)
FIG. 37 UK genitourinary drugs market, 2013 - 2024 (USD Million)
FIG. 38 Asia Pacific genitourinary drugs market, 2013 - 2024 (USD Million)
FIG. 39 Japan genitourinary drugs market, 2013 - 2024 (USD Million)
图40中国泌尿生殖器的毒品市场,2013 - 2024 (USD Million)
FIG. 41 India genitourinary drugs market, 2013 - 2024 (USD Million)
FIG. 42 Latin America genitourinary drugs market, 2013 - 2024 (USD Million)
FIG. 43 Brazil genitourinary drugs market, 2013 - 2024 (USD Million)
FIG. 44 Mexico genitourinary drugs market, 2013 - 2024 (USD Million)
FIG. 45 MEA genitourinary drugs market, 2013 - 2024 (USD Million)
FIG. 46 South Africa genitourinary drugs market, 2013 - 2024 (USD Million)
FIG. 47 Participant categorization